According to a research done by U.S Food and Drug Administration (FDA) on Type 2 Diabetes Patients at risk of disability, those who use of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes management. Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) or gliptins, are a class of oral hypoglycemics that block DPP-4. They work by reducing glucagon and blood glucose levels in patients with type 2 diabetes.
It has been observed that the type 2 diabetes medicines Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin may cause joint pain that can be severe and disabling, as a result FDA have added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Action required from Prescriber/Patients
- Health care professionals should consider DPP-4 inhibitors as a possible cause of severe joint pain and discontinue the drug if need be.
- If you have been using this products and notice any adverse effect, Report adverse events or side effects related to the use of these products to immediately to the appropriate health authority.